

Cite this: *Chem. Sci.*, 2015, 6, 804Kinetically selective inhibitors of histone
deacetylase 2 (HDAC2) as cognition enhancers†F. F. Wagner,^a Y.-L. Zhang,^a D. M. Fass,^{ac} N. Joseph,^{ab} J. P. Gale,^a M. Weiwer,^a
P. McCarren,^a S. L. Fisher,^c T. Kaya,^a W.-N. Zhao,^{ad} S. A. Reis,^{ad} K. M. Hennig,^{ad}
M. Thomas,^a B. C. Lemerrier,^a M. C. Lewis,^a J. S. Guan,^{ab} M. P. Moyer,^a E. Scolnick,^a
S. J. Haggarty,^{ad} L.-H. Tsai^{ab} and E. B. Holson^{*a}

Aiming towards the development of novel nootropic therapeutics to address the cognitive impairment common to a range of brain disorders, we set out to develop highly selective small molecule inhibitors of HDAC2, a chromatin modifying histone deacetylase implicated in memory formation and synaptic plasticity. Novel *ortho*-aminoanilide inhibitors were designed and evaluated for their ability to selectively inhibit HDAC2 *versus* the other Class I HDACs. Kinetic and thermodynamic binding properties were essential elements of our design strategy and two novel classes of *ortho*-aminoanilides, that exhibit kinetic selectivity (biased residence time) for HDAC2 *versus* the highly homologous isoform HDAC1, were identified. These kinetically selective HDAC2 inhibitors (**BRD6688** and **BRD4884**) increased H4K12 and H3K9 histone acetylation in primary mouse neuronal cell culture assays, in the hippocampus of CK-p25 mice, a model of neurodegenerative disease, and rescued the associated memory deficits of these mice in a cognition behavioural model. These studies demonstrate for the first time that selective pharmacological inhibition of HDAC2 is feasible and that inhibition of the catalytic activity of this enzyme may serve as a therapeutic approach towards enhancing the learning and memory processes that are affected in many neurological and psychiatric disorders.

Received 17th July 2014
Accepted 10th September 2014

DOI: 10.1039/c4sc02130d

www.rsc.org/chemicalscience

Introduction

Mounting evidence, generated over the past decade, supports the critical role of chromatin modification and gene expression regulation in the molecular mechanisms underlying synaptic plasticity and memory formation.¹ Dysregulation of these neurobiological processes manifest as a variety of cognitive phenotypes in a host of diseases including Alzheimer's disease (neurodegenerative²), schizophrenia³ (psychiatric), post-

traumatic stress disorder (PTSD)⁴ (psychiatric), Rubinstein-Taybi and Rett's syndrome⁵ (intellectual disability). The learning and/or memory impairments associated with these disorders represent a profound unmet medical need that is not effectively ameliorated by current approved treatments. According to the 2014 Alzheimer's disease facts and figures report, the prevalence of AD alone is estimated to triple by 2050 and affect more than 13 million individuals in the United States. New treatments which focus beyond the slowing of disease progression in AD and are more broadly applicable across disease states are sorely needed. Because learning and memory processes require active gene transcription and subsequent protein synthesis to establish long-lasting changes in synapses, biological targets which affect gene expression are attractive for pharmacological intervention. Several chromatin modifying enzymes have been implicated in the neurobiology of learning and memory, in particular, histone deacetylases (HDACs).^{1,6} HDACs are responsible for catalyzing the post-translational hydrolysis of acetyl groups from the ϵ -nitrogen of lysine residues located on histone as well as non-histone proteins.⁷⁻⁹ The metal-dependent isoforms are categorized as follows: Class I (HDACs 1, 2, 3 and 8), Class IIa (HDACs 4, 5, 7, 9), Class IIb (HDACs 6, 10) and Class IV (HDAC11).⁷ The dysregulation of histone acetylation is a feature associated with a range of neurological disorders.⁶ For example, Rubinstein-

^aStanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts, USA. E-mail: edholson@broadinstitute.org^bPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA^cSL Fisher Consulting, LLC, PO Box 3052, Framingham, Massachusetts, USA^dChemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA† Electronic supplementary information (ESI) available: Compound synthesis and characterization; ¹H NMR spectra, HPLC or UPLC spectral traces; HDAC enzymatic assay protocol; IC₅₀s for representative compounds for HDACs 1–9; full kinetic parameters for **BRD4884** and **BRD6688**; progression and dissociation curves for **BRD6688**; pharmacokinetic graphs and parameters for representative compounds; kinetic selectivity profiles for **BRD4884** and **BRD6688**; *in vitro* pharmacology, pharmacokinetic protocols; target engagement simulation protocol; molecular modelling and docking protocols; neuronal cell based assay protocol, behavioural studies protocols. See DOI: 10.1039/c4sc02130d

Taybi Syndrome (RTS), a rare human genetic disorder, is caused by mutations in the histone acetyltransferase (HAT) domain of the CREB-binding protein (CBP) gene.¹⁰ This loss of function mutation leads to a hypoacetylation state, in transgenic mice, that phenocopies cognitive deficits observed in humans. As a therapeutic proof of principle, the hypoacetylation in brain and the corresponding cognitive deficits in these mice can be rescued through the administration of SAHA, a non-selective Class I, IIb HDAC inhibitor. Subsequently, several groups demonstrated that administration of non-selective inhibitors, primarily SAHA and the Class I inhibitor sodium butyrate, can rescue the cognitive deficits in learning and memory behavioral paradigms for a variety of transgenic mouse models.^{11–15} Most recently, Gräff *et al.* show that treatment with CI-994, an HDAC1, 2 and 3 inhibitor, triggers the upregulation of a key set of neuroplasticity-related genes and was efficacious in fear extinction models of PTSD.⁴ A key question underlying the effects of these non-selective HDAC inhibitors is whether they are driven by the inhibition of a single or a combination of HDAC isoforms.

Among the Class I and Class IIb isoforms, knockout and/or over-expression transgenic mouse models of HDAC2,^{12,16} HDAC3¹⁵ and HDAC6^{11,13} have demonstrated that loss of function of these individual isoforms can enhance memory and synaptic plasticity. While selective inhibitors of HDAC3 and HDAC6 have been described and in some cases demonstrated *in vivo* efficacy in mouse models of learning and memory, there are no such tools available for probing the selective inhibition of HDAC2 in the brain.¹⁷ Additionally, Tsai and co-workers demonstrated that HDAC1 activity may be neuroprotective,¹⁸ reinforcing the importance of selective inhibition within the class I isoforms. Intrigued by the opportunity for pharmacological intervention in psychiatric diseases characterized by a cognitive impairment component, and the increasing evidence implicating the role of HDAC2 in learning and memory, we set out to identify selective small molecule inhibitors of HDAC2.

Results and discussion

The development of highly potent and isoform selective HDAC inhibitors is critical not only to refine our understanding regarding the relevant isoform(s) for *on-target efficacy* but also to mitigate potential mechanism-based, dose-limiting side effects (thrombocytopenia, fatigue) caused by the inhibition of multiple HDACs, particularly HDACs 1 and 2.¹⁹ Among the Class I HDACs (HDACs 1, 2, 3 and 8), HDAC 1 and 2 share the highest overall sequence similarity (86%) and display 95% similarity within the Zn²⁺ catalytic binding domain.⁷ At the outset, we believed imparting sufficient selectivity between these two highly similar isoforms presented the greatest chemical challenge for small molecule binders targeting the HDAC catalytic binding domain. As part of our design strategy, we emphasized the kinetic (residence time) and thermodynamic binding properties of our inhibitors for HDACs 1, 2 and 3. Binding kinetics and residence times are important considerations when developing therapeutics.²⁰ Compound residence time at the target of interest can dictate efficacy while its residence time






at homologous target(s) could affect potential adverse effects. Ideally, a selective HDAC2 inhibitor would demonstrate both thermodynamic (K_i or IC_{50} values) and kinetic selectivity (residence time) favoring HDAC2. Another major challenge in CNS drug discovery, highlighted by the pharmacokinetic shortcomings of SAHA, is the efficient delivery of small molecules across the blood brain barrier (BBB). Consequently, our inhibitor design hinged on a multi parametric optimization of highly brain penetrant and selective inhibitors of HDAC2 *versus* all other Zn-dependent HDACs, paying particular attention to HDAC1.

While there are several chemical classes of HDACi, we chose to focus our medicinal chemistry efforts on the *ortho*-aminoanilide class of inhibitors. *Ortho*-aminoanilides, exemplified by CI-994 (Table 1), are sub-Class I selective, inhibiting only HDAC1, 2 and 3, with no activity towards HDAC8 or the Class IIa and IIb HDAC isoforms (ESI Table 1†). Several groups have described HDAC1, 2 selective *ortho*-aminoanilides, exemplified by compound **1** (Table 1).^{21–23} The C-5 thiophene moiety, in compound **1**, occupies a 14 Å internal cavity in HDACs 1 and 2 leading to improved selectivity and potency for these two isoforms. In addition, *ortho*-aminoanilides display slow binding kinetics.^{24–28} For example, compound **1** displays potent *in vitro* inhibition towards human recombinant HDACs 1 and 2 with pseudo-irreversible binding kinetics (Table 1; residence time determined through progression curve analysis for HDAC catalyzed deacetylation at various concentrations of inhibitor, see ESI†). Finally, *ortho*-aminoanilides are highly synthetically tractable and possess more desirable pharmacokinetic properties than other known HDAC inhibitor chemotypes.^{17,29}

In an effort to understand the contribution of the core binding motifs in **1** and maximize ligand efficiency in our design, we set out to identify the minimal pharmacophoric elements that confer potency for HDAC2.³⁰ Starting from **1** (ligand efficiency (ligE) = 0.32 for HDAC2) we designed a series of truncated analogs starting from the solvent exposed acetamide motif (Table 1). Removal of the capping acetamide group provided compound **2**, which retained moderate to good potency for HDACs 1, 2 and 3 (2, IC_{50} = 0.023 μM, 0.129 μM and 1.68 μM, respectively). Truncating further by removing the phenyl linking motif provided compound **3**, which displayed weak to moderate potency for HDACs 1, 2 and 3 (3, IC_{50} = 0.335 μM; 8.71 μM and 0.665 μM, respectively). Accordingly, the ligand efficiencies of this truncated series for HDAC2 remains high (≥ 0.32). Finally, the biaryl-dianiline **4** displayed no inhibitory activity towards HDACs 1, 2 and 3. Intrigued by the ability of the highly efficient small molecule ligand **3** to bind HDAC1, 2 and 3, we performed molecular docking simulations into HDAC2 (3MAX structure)²¹ (Fig. 1A). Compound **3** achieves optimal chelation geometry establishing an intricate network of H-bonds with His145, His146 and Gly 154 (Fig. 1A and B). The docked structure demonstrates that the methyl amide is not only accommodated but provides a rigid vector aligned with the hydrophobic 11 Å channel (Fig. 1A) leading to the solvent exposed surface (Fig. 1B). On the basis of this model, we speculated that sp³-rich substituents projecting along this



Table 1 Defining the essential HDAC binding elements of *ortho*-aminoanilides

Compound	Structure	HDAC isoform inhibition IC ₅₀ ^a (μM)			Ligand efficiency ^b (ligE) HDAC1/HDAC2
		HDAC1	HDAC2	HDAC3	
Cl-994		0.041 ± 0.012	0.147 ± 0.066	0.046 ± 0.018	0.37/0.34
1		0.001 ± 0.001 >2400	0.013 ± 0.009 Residence time T_{1/2} (min) ~4800	0.398 ± 0.105 ~1200	0.36/0.32
2		0.023 ± 0.008	0.129 ± 0.006	1.68 ± 0.26	0.36/0.33
3		0.355 ± 0.012	8.71 ± 3.16	0.665 ± 0.063	0.40/0.32
4		>33.33	>33.33	>33.33	

^a Values are the mean of a minimum of two experiments. Data are shown as IC₅₀ values in μM ± standard deviation. Compounds were tested in duplicate in a 12-point dose curve with 3-fold serial dilution starting from 33.33 μM. ^b Ligand efficiency (ligE) = (−log IC₅₀)/number of non-hydrogen atoms.

molecular trajectory would provide novel chemotypes and impart structure–activity relationships which were largely unexplored.

While other sp³-linked *ortho*-aminoanilides have been described, they possess extended linker and capping groups that project beyond the 11 Å channel.³¹ We chose to focus our Structure Activity Relationship (SAR) efforts on the linker portion of the molecule occupying the 11 Å channel. To modulate compound properties (both physicochemical and binding kinetics), we chose three 14 Å internal cavity motifs: a 2-thienyl and *p*-fluorophenyl group, both of which are hydrophobic, and a more hydrophilic 4-pyridyl group.

Encouraged by the initial results with acetyl compound 3, we were inspired to chemically map the 3D topography of the linker region visibly available in our computational model (Fig. 1) to

probe linker effects on potency, selectivity and kinetic binding, as well as the interplay with 14 Å internal cavity motifs. Using small sp³ rich linker groups (non-aromatic), we systematically explored the 11 Å channel (Table 2).

An isopropyl (compound 5) coupled with the 2-thienyl 14 Å internal cavity motif afforded a 6 to 33-fold improvement in potency for HDAC1 and 2 with modest selectivity *versus* HDAC3 (Table 2). This gain of potency combined with the minimal atomic size of this group maintained excellent ligand efficiency of 0.37. However, the *tert*-butyl compound 6 exceeded the steric limits of the channel and led to a significant loss in potency against HDAC1, 2 and 3. In contrast, the constrained cyclopropyl group (compound 7) afforded a dramatic 100-fold improvement in potency for HDAC2.






Fig. 1 (A) Cross sectional view of compound **3** docked into catalytic binding domain of HDAC2 (B) surface view of compound **3** docked into HDAC2 showing the trajectory of the sp^3 methyl amide into the 11 Å channel. Hydrogen bonding interactions are shown as yellow dotted lines. The electrostatic surface of HDAC2: blue = hydrophobic regions; red = negatively charged regions.

Increasing linker ring size (compounds **8–10**) combined with hydrophobic (*p*-fluorophenyl or 2-thienyl) 14 Å internal cavity motifs increased potency on HDAC1 only, suggesting that larger hydrophobic and sp^3 -rich linkers are tolerated in HDAC2 but do not provide additional binding energy. Contrary to observations in the hydroxamic acid chemical series,³² sp^2 -hybridization α to the carbonyl in **BRD2283** had minimal effect on the inhibitor activity towards Class I HDACs. The addition of hydrophilic linker groups gave mixed effects towards binding affinity. The basic *N*-methyl piperidine (compound **11**) was not tolerated as its inhibitory activity on all HDACs suffered a ≥ 80 -fold loss. The highly hydrophobic 11 Å channel, lined by two phenylalanines (Fig. 1), does not tolerate the hydrophilic piperidine ring which is protonated at physiological pH. In contrast, the neutral *N*-acetylpiperidine (**BRD3349**) or pyran (**BRD4884**) derivatives provided highly potent and selective HDAC1, 2 inhibitors (Table 2, **BRD4884**: IC_{50} 0.029 μM and 0.062 μM on HDAC1 and HDAC2 respectively with ≥ 17 -fold selectivity *versus* HDAC3). Interestingly, replacement of the *p*-fluorophenyl with a 4-pyridyl as an internal cavity motif (*cf.* **BRD4884** to compound **12**) reduced potency on HDAC1, 2 and 3 by 18 to 80-fold. In this carbamate series, the combination of sp^3 -rich linker with a 14 Å cavity hydrophobic aryl group is preferred, affording highly potent and selective HDAC1 and 2 inhibitors. Next, we evaluated the *in vitro* kinetic binding properties towards HDACs 1, 2 and 3, through progression curve analyses at various inhibitor concentrations and substrate conversion dilution experiments monitored continuously for 4 hours. Analysis of **BRD4884** kinetic parameters revealed slow-on/slow-off kinetics for HDAC2, but a shift to fast-on/faster-off kinetics for HDAC1, leading to a 7-fold longer half-life on HDAC2 ($T_{1/2}$ 143 min) *versus* HDAC1 ($T_{1/2}$ 20 min; Table 2 and ESI Table 2†). This binding profile provides kinetic selectivity for HDAC2 and good thermodynamic selectivity for HDAC1, 2 *versus* HDAC3. Further characterization of **BRD4884** in mice revealed good pharmacokinetic properties ($T_{1/2}$ = 0.9 hours) including excellent brain

permeability (brain-to-plasma ratio of 1.29 based on AUC, see ESI Fig. 1†) and a moderate predicted free fraction (6%) in brain based on a tissue binding assay.






Intrigued by the potency and kinetic selectivity towards HDAC2 of these sp^3 -rich carbamate-linked inhibitors, we investigated whether the hydrophobic 11 Å channel could tolerate alternative chemotypes such as carbamates and ureas (Table 3).

We anticipated that these alternate chemotypes would affect the electronic nature of the carbonyl moiety and negatively influence its' ability to effectively chelate zinc. To our surprise, propyl carbamate **13** was an effective inhibitor of HDAC1 and 2 with low micromolar potencies. While an extensive exploration of the SAR in the carbamate series did not lead to selective HDAC2 inhibitors, it did produce potent HDAC1, 2 inhibitors. Compound **14** represents the most potent and selective HDAC1, 2 inhibitor of the carbamate series (Table 3; IC_{50} 0.069 and 0.104 μM on HDAC1 and 2 respectively with 8-fold selectivity *versus* HDAC3).

Next we turned our attention to the nitrogen ortholog of carbamate **13** to explore the influence of alternative heteroatoms at this position. Propyl urea **15** and the *N*-methylated analog **16** displayed low micromolar potencies for HDAC1 and 2. On the basis of our computational models defining the topology of the 11 Å channel (Fig. 1B) and the observed SAR in the carbamate series we next examined conformationally constrained ureas. Cyclizing the *N*-Me motif in compound **16** onto the terminal propyl carbon provided compound **17**, which displayed excellent potency and selectivity for HDACs 1, 2 (Table 3; IC_{50} 0.010 and 0.059 μM on HDAC1 and 2 respectively with 25-fold selectivity *versus* HDAC3). Interestingly the smaller azetidine linked ureas, **BRD3321** and **BRD0302**, combined with a *p*-fluorophenyl 14 Å cavity motif demonstrated >12 -fold selectivity for HDAC1 over HDAC2 (**BRD0302** HDAC1 K_i = 0.111 μM *vs.* HDAC2 K_i = 2.74 μM , 25-fold selectivity, no kinetic selectivity was observed). These compounds



linker
R¹
internal cavity motif
P²
zinc-binding group
NH₂

Compound	R ¹ group	R ² group	HDAC isoform inhibition IC ₅₀ ^a (μM)			[Brain]/[plasma] and brain free fraction ^b (%)
			HDAC1	HDAC2	HDAC3	
5			0.059 ± 0.015	0.261 ± 0.140	0.949 ± 0.034	nd
6			4.24 ± 0.257	3.13 ± 0.492	25.0 ± 1.71	nd
7			0.072 ± 0.029	0.086 ± 0.057	0.350 ± 0.018	nd
8			0.020 ± 0.003	0.131 ± 0.015	0.548 ± 0.162	nd
9			0.011 ± 0.005	0.095 ± 0.061	0.635 ± 0.308	nd
BRD2283			0.003 ± 0.002	0.054 ± 0.016	0.604 ± 0.039	nd
10			0.021 ± 0.005	0.079 ± 0.042	1.01 ± 0.16	nd
11			11.9 ± 1.17	13.23 ± 0.45	>33.33	nd
BRD3349			0.011 ± 0.003	0.049 ± 0.005	2.78 ± 0.02	0.04
BRD4884			0.029 ± 0.012	0.062 ± 0.031	1.09 ± 0.38	1.29
			20	143	257	6%
12			2.36 ± 0.151	1.10 ± 0.019	>33.33	nd

^a Values are the mean of a minimum of two experiments. Data are shown as IC₅₀ values in $\mu\text{M} \pm$ standard deviation. Compounds were tested in duplicate in a 12-point dose curve with 3-fold serial dilution starting from 33.33 μM . nd = not determined. ^b Brain free fraction estimated based on brain tissue binding experiments.

represent some of the most thermodynamically selective HDAC1 inhibitors reported to date and reinforce the notion that differentiation between these two isoforms is possible. An important SAR distinction in the urea series *versus* the



carbamide series is that heteroaromatic internal cavity motifs (*cf.* **BRD6688** vs. compound **17**) retain potency towards HDAC1 and 2 (ligE = 0.33) allowing us to tune physicochemical properties through substitutions in this portion of the

Table 3 Structure–activity relationships for carbamate and urea based HDAC inhibitors³⁰

Compound	R ¹ group	R ² group	HDAC isoform inhibition IC ₅₀ ^a (μM)			[Brain]/[plasma] and brain free fraction ^b (%)
			HDAC1	HDAC2	HDAC3	
13			0.611 ± 0.253	1.00 ± 0.34	2.60 ± 0.09	nd
14			0.069 ± 0.031	0.104 ± 0.028	0.861 ± 0.141	nd
15			0.071 ± 0.009	2.64 ± 1.13	13.05 ± 3.04	nd
16			0.216 ± 0.050	0.912 ± 0.155	13.2 ± 2.19	nd
17			0.010 ± 0.002	0.059 ± 0.021	1.47 ± 0.25	nd
BRD3321			0.019 ± 0.005	0.233 ± 0.053	1.75 ± 0.25	nd
BRD0302			0.113 ± 0.015 0.111 308	1.29 ± 0.55 Ki (μM) 2.74 Residence time T_{1/2} (min) 375	9.22 ± 2.06 17.7 231	nd
BRD6688			0.021 ± 0.013 65	0.100 ± 0.048 Residence time T_{1/2} (min) 381	11.48 ± 2.54 280	0.26 54%
18			0.093 ± 0.022	0.176 ± 0.100	10.15 ± 3.27	nd
19			0.024 ± 0.001	0.271 ± 0.086	1.96 ± 1.34	nd
BRD3227			0.043 ± 0.024	0.291 ± 0.141	23.5 ± 6.7	0.01
20			0.035 ± 0.012 165	0.238 ± 0.107 Residence time T_{1/2} (min) 513	5.07 ± 0.93 495	0.19 21%
BRD3386			0.026 ± 0.007 570	0.178 ± 0.058 Residence time T_{1/2} (min) 660	3.13 ± 0.90 495	0.34 22%



Table 3 (Contd.)

Compound	R ¹ group	R ² group	HDAC isoform inhibition IC ₅₀ ^a (μM)			[Brain]/[plasma] and brain free fraction ^b (%)
			HDAC1	HDAC2	HDAC3	
BRD8951			0.001 ± 0.001	0.011 ± 0.003	0.544 ± 0.205	0.27 2%
			2100	788	ND	
BRD4161			0.007 ± 0.002	0.045 ± 0.010	3.46 ± 0.89	0.11 23%
			430	788	770	

^a Values are the mean of a minimum of two experiments. Data are shown as IC₅₀ values in μM ± standard deviation. Compounds were tested in duplicate in a 12-point dose curve with 3-fold serial dilution starting from 33.33 μM. nd = not determined. ^b Brain free fraction estimated based on brain tissue binding experiments.

molecule. Additionally, the 4-pyridyl motif in **BRD6688** provides increased selectivity for HDACs 1 and 2 (≥115-fold) reflected by an HDAC3 IC₅₀ of 11.4 μM. More importantly, **BRD6688** possesses preferential binding kinetics with extended half-life on HDAC2 compared to HDAC1 (381 min *versus* 65 min, 6-fold selectivity). To determine the optimal cyclic urea motif, we synthesized piperidine and morpholine analogs **18–20** and **BRD3227** which led to a slight loss in potency on both HDAC1 and 2. In HDAC2, the apparent steric limit presented by a 6-membered linker group in the 11 Å channel and the corresponding loss in potency could not be compensated for by the use of a hydrophobic 14 Å cavity group (compound **19**) and/or by ring substitutions (*e.g.* morpholine in compound **20** and 4-acetamide in **BRD3227**). Also, no significant increase in potency was observed when using the sterically less demanding oxa-aza-spiroheptane ring³³ in **BRD3386** as an alternative to the morpholine. In order to minimize sp³ steric components and capitalize on potential π–π interactions with Phe 155 and 210 which line the 11 Å channel (Fig. 1A and B), we synthesized isoindoline ring systems (**BRD8951** and **BRD4161**). These compounds displayed improved potency on both HDAC1 and HDAC2 irrespective of the nature of the internal 14 Å cavity motif. Analysis of the isoform binding kinetics of these more potent HDAC1, 2 inhibitors showed no kinetic selectivity and presented no improvement relative to **BRD6688**.

We have identified and characterized the first kinetically selective HDAC2 inhibitors in two novel and distinct chemical series (full binding kinetics provided in ESI Table 2†). The carbamide **BRD4884** and the urea **BRD6688** possess selective binding kinetics for HDAC2 (*T*_{1/2} = 143 and 381 min respectively) compared to the highly homologous isoform HDAC1 (*T*_{1/2} = 20 and 65 min respectively). Interestingly, these kinetically selective HDAC2 *ortho*-aminoanilide based inhibitors rely on

the incorporation of sp³-rich linker motifs coupled with aryl and/or heteroaryl 14 Å cavity motifs. Both compounds show excellent HDAC2 thermodynamic selectivity *versus* other Class I (>17-fold) and Class II (>500-fold) HDAC isoforms tested (ESI Table 1†). Moreover, **BRD4884** and **BRD6688** display good to excellent brain penetration (ESI Fig. 1†), low brain tissue binding, low potential cardiac toxicity, and high specificity *versus* a broad panel of biological targets (Tables 2 and 3 and ESI Table 3†). To better define HDAC isoform selectivity in brain we integrated the *in vitro* kinetic binding parameters, *in vivo* pharmacokinetic properties (including brain free fraction) and the HDAC enzyme concentration in brain³⁴ by simulating target engagement profiles over time using numerical integrations over a system of differential equations describing the distribution of enzyme states (Fig. 2, see ESI for detailed description of method and input parameters†). Good correlation between *in vitro* and *in vivo* derived kinetic binding parameters for small molecule inhibitors of HDACs 1, 2 and 3 has been demonstrated using brain tissue autoradiography.³⁴

The simulated target engagement profiles for both compounds are characterized by three phases of kinetic selectivity (ESI Fig. 2†); an initial phase (*t* = 0–60 min) of good kinetic selectivity for HDAC1 (**BRD4884**, 3.5–30-fold, **BRD6688**, 2.5–20-fold), an intermediate crossover stage with equivalent target engagement levels for HDAC1 and 2, followed by a terminal phase (**BRD4884**, *t* > 3 h; **BRD6688**, *t* > 6 h) of high and sustained kinetic selectivity for HDAC2 (**BRD4884**, 20–1000X; **BRD6688**, 3–50-fold). Both compounds exhibit high kinetic selectivity against HDAC3 throughout the simulation. There is, however, a substantial difference between the two compounds in the magnitude of HDAC2 target engagement, which is driven by differences in the measured free fraction (**BRD6688**, *f*_u = 0.54; **BRD4884**, *f*_u = 0.06) and, to a lesser extent, the slower on and






Fig. 2 Simulated target engagement profiles for HDAC1, 2 and 3 in brain for BRD4884 and BRD6688 at 10 mg kg⁻¹ dose.

off-rate for **BRD6688**. **BRD6688** attains greater than 50% HDAC2 engagement for several hours whereas **BRD4884** achieves no more than 10% HDAC2 engagement. Taken together, these compounds represent the state of the art HDAC2 selective inhibitors to probe the function of HDAC2 in brain *via* small molecule modulation.

To further validate the activity of these compounds, we investigated whether the *in vitro* biochemical activities against human recombinant enzymes and their respective kinetic profiles translated to functional cell based assays by measuring histone acetylation changes.

H3K9 and H4K12 have been implicated as potential HDAC2 substrates in HDAC2 KO and OE transgenic mice.¹² However, these histone loci display acetylation changes in response to non-selective HDAC2 inhibitor treatment^{35,36} demonstrating the non-specific nature of these loci towards HDAC2. Primary mouse forebrain neuronal cultures were treated with **BRD4884** and **BRD6688** (10 μ M for 24 h) and monitored for acetylation changes at H3K9 and H4K12 relative to the vehicle control (Fig. 3).




Fig. 3 Increased acetylation of histones H4K12 and H3K9 in mouse forebrain primary neuronal cultures following treatment with kinetically selective HDAC2 inhibitors **BRD4884** and **BRD6688** (10 μ M, 24 hours). Average of two experiments run in triplicates from separate dissections and cultures.

Treatment with **BRD4884** or **BRD6688** produced significant increases in AcH4K12 and AcH3K9 confirming the inhibitory activity of these compounds towards endogenous HDACs. While these histone acetylation increases are indicative of HDAC inhibition, it is not clear whether these changes are driven solely through modulation of HDAC2 or through a combination of HDACs including HDACs 1 and 3. We speculate that the attenuated change in AcH3K9 demonstrated by **BRD6688** (*cf.* **BRD4884**) is due in part to its' superior selectivity for HDAC2 relative to HDAC3, the most highly expressed HDAC isoform in the brain.³⁷

To further characterize the translational potential of kinetically selective HDAC2 inhibitors in cognitive disorders, **BRD4884** and **BRD6688** were evaluated in CK-p25 mice, a murine model of neurodegeneration with profound deficits in spatial and associative memory.^{38,39} Overexpression of p25 protein is controlled by a doxycycline-repressed, calcium/calmodulin-dependent protein kinase II (CaMKII) promoter.³⁸ Six week induction recapitulates many hallmark features of Alzheimer's disease, including progressive neuronal loss, tau pathology, β -amyloid accumulation, cognitive dysfunction and impaired synaptic plasticity.^{2,39,40} Daily treatment for 10 days with **BRD4884** or **BRD6688** (10 and 1 μ g kg⁻¹, i.p. dosing respectively, Fig. 4A), rescued the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning, a hippocampal dependent form of learning (Fig. 4B). Remarkably, **BRD6688** daily compound treatment at 1 mg kg⁻¹ in p25 induced animals restored the freezing response to normal levels compared to the vehicle treated non-induced p25 littermates (red vs. white bar).

Furthermore, compound treatment corresponded with increased H4K12 acetylation in hippocampal CA1 neurons compared to the vehicle treated group (Fig. 3C and D, **BRD6688** treatment effect was significant in paired *t*-test). Taken together, our results demonstrate that these novel and kinetically selective HDAC2 inhibitors engage HDACs in the brain and elicit acetylation changes at doses that produce enhanced learning behaviors in cognitively challenged mice.







Fig. 4 A. Study design for CK-p25 induced neurodegenerative model and testing in contextual fear conditioning paradigm. (B) BRD4884 and BRD6688 enhance freezing time in CK-p25 mice in a contextual fear conditioning behavioral paradigm. One-way ANOVA comparison followed by Dunnett's posthoc analysis; * $p < 0.05$; n is depicted in each bars. (C) Hippocampal sections from CK-p25 mice after 10 day treatment with BRD6688 demonstrate increased H4K12 acetylation (paired t -test). (D) Quantitation of increased acetylation in hippocampal slices after BRD6688 treatment.

Conclusions

Here we demonstrate for the first time that the selective inhibition of histone deacetylase 2 (HDAC2) (*versus* all other zinc dependent HDACs) is feasible. Starting with the *ortho*-amino-anilide chemical series and focusing on a linker-centric strategy, we developed highly optimized compounds suitable for CNS applications. Remarkably, we demonstrated that the binding kinetics of these inhibitors towards individual isoforms is tunable through a combination of linker and internal 14 Å cavity motifs. These structural combinations, exemplified by BRD4884 and BRD6688, demonstrate kinetic selectivity for HDAC2 *vs.* HDAC1, an isoform with 95% similarity within the catalytic binding domain. In addition, these kinetically selective HDAC2 inhibitors increased histone acetylation (H4K12 and H3K9) in primary mouse neuronal cultures as well as in hippocampal CA1 neurons in CK-p25 mice. The increased histone acetylation in brain serves as a surrogate pharmacodynamic marker of HDAC engagement and was consistent with our observed brain pharmacokinetic properties.

We demonstrated that HDAC2 selective inhibitors rescue the cognitive deficits in CK-p25 mice, a model of neurodegeneration; in a Pavlovian fear conditioning behavioral assay. The cognitive improvements observed in these hippocampal-

dependent memory processes recapitulate previous results reported by Guan *et al.* on the effects elicited *via* the genetic knockout of HDAC2,¹² as well as through targeted RNA interference (RNAi)-mediated HDAC2 gene silencing selectively within the hippocampus.² Our studies suggest that a sustained low level of HDAC2 engagement (~10% for BRD4884) by an orthosteric kinetically biased small molecule inhibitor is sufficient for biological activity. While these compounds demonstrate sufficient selectivity *versus* HDAC3 to preclude its' role in the biological effects observed, these compounds, particularly BRD4884, do not achieve sufficient selectivity *versus* HDAC1. It is possible that the intermittent inhibition of HDAC1 may play a role in the effects observed. Clearly experimental efforts are needed to confirm these target engagement profiles *in vivo*. Taken together, our studies suggest that the pharmacological inhibition of HDAC2 may enhance learning and memory and potentially rescue the observed cognitive deficits in multiple neuro-psychiatric disorders such as schizophrenia and PTSD. Additionally, isoform selective inhibitors may mitigate some of the known mechanism-based toxicological effects associated with the inhibition of multiple HDACs, particularly the concomitant inhibition of HDAC1 and 2.⁴¹ Also, future studies will determine the potency and selectivity of this class of HDAC inhibitors towards distinct Class I HDAC complexes that are



known to exist in the brain and play different biological functions.¹²

Our studies open the way for the design of highly ligand efficient and selective small molecule HDAC inhibitors optimized for central nervous system disorders. In AD, while drugs targeting the clearance of β -amyloid have failed to slow disease progression and improve cognitive measures; combination therapy with HDAC2 selective inhibitors could potentially restart synaptic function and memory formation. These novel small molecule inhibitors can be used as tools for probing the biological functions and relevance of the different HDAC isoforms and will catalyze the evaluation of their therapeutic potential in treating neurological disorders.

Experimental

Synthetic procedures

Detailed synthetic procedures are described in ESI.†

Materials and methods

HDAC inhibition assays. All recombinant human HDACs were purchased from BPS Bioscience. The substrates, Broad Substrate A, and Broad Substrate B, were synthesized in house. All the other reagents purchased from Sigma. Caliper EZ reader II system was used to collect all data. Compounds were tested in duplicate in a 12-point dose curve with 3-fold serial dilution starting from 33.33 μ M. Purified HDACs were incubated with 2 μ M carboxyfluorescein (FAM)-labeled acetylated or tri-fluoroacetylated peptide substrate (Broad Substrate A and B respectively) and test compound for 60 min at room temperature, in HDAC assay buffer that contained 50 mM HEPES (pH 7.4), 100 mM KCl, 0.01% BSA and 0.001% Tween-20. Reactions were terminated by the addition of the known pan HDAC inhibitor LBH-589 (panobinostat) with a final concentration of 1.5 μ M. Substrate and product were separated electrophoretically and fluorescence intensity in the substrate and product peaks was determined and analyzed by Labchip EZ Reader. The reactions were performed in duplicate for each sample. IC₅₀ values were automatically calculated by Origin8 using 4 Parameter Logistic Model. The percent inhibition was plotted against the compound concentration, and the IC₅₀ value was determined from the logistic dose-response curve fitting by Origin 8.0 software.

Binding kinetic measurements. Slow, tight-binding kinetics of **BRD6688** and **BRD4884** with HDACs 1, 2, and 3 were evaluated by reaction progression curves and dilution experiments. To determine the mechanism and associated kinetic values, a series of progress curves of HDACs 1, 2 or 3 inhibition were generated in the presence of **BRD6688** or **BRD4884** at different concentrations. The off-rates of **BRD6688** and **BRD4884** were determined from dilution experiments. See ESI for full details.†

Neuronal histone acetylation assays. Measurements of increases in neuronal histone acetylation in mouse forebrain primary neuronal cultures induced by HDAC inhibitor compounds was performed exactly as described in Fass *et al.*, (2013). On the 13th day after generating the cultures, cells

were treated for 24 hours with compounds at 10 μ M. Cells were fixed with formaldehyde, stained with antibodies to acetyl-histone H3, lysine 9 (AcH3K9), or acetyl-histone H4, lysine 12 (AcH4K12), and green fluorescent secondary antibodies, and cellular fluorescence signals were quantitated with an Acumen microcytometer. To determine the efficacy of HDAC inhibitor compounds, we calculated the percentage of compound-treated cells with a fluorescence signal above a baseline threshold established in vehicle (DMSO)-treated cells.


CK-p25 induction. All procedures involving animals followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Massachusetts Institute of Technology Animal Care and Use Committee. Mice at 3 months of age, CK-p25 male mice were induced for 6 weeks to obtain forebrain-specific expression of p25 (Cruz *et al.*, 2003). Littermates lacking p25 were used as controls. All mice were heterozygous for their respective genes.

Context-dependent fear conditioning. Training consisted of habituating the mice to the conditioning box (TSE Systems) for a period of 3 min, which was followed by a foot shock (2 s; 0.8 mA; constant current). The shock was repeated 30 s later and the mice were allowed to remain in the box for an additional 15 s. To assess associative learning, a long-term memory test was performed 24 h later by re-exposing the mice for 3 min to the conditioning context, while measuring freezing behaviour (Gräff *et al.*, 2012).

Administration of compounds. **BRD6688** and **BRD4884** were dissolved in DMSO (5% of the total resultant solution) and then diluted in 30% Cremophor/65% in physiological saline (H₂O containing 0.9% NaCl (Sigma)), for a final dosage solution of 1 mg kg⁻¹ and 10 mg kg⁻¹, respectively. Vehicle solutions consisted of the forementioned solution without the compounds. Solutions were prepared immediately before injection and administered daily *via* intraperitoneal injection for a period of 10 days prior to behaviour.

Immunohistochemistry. Immunohistochemistry was performed essentially as described in Gräff *et al.*, 2012, 2014. Coronal brain slices (40 μ m thickness) were permeabilized with 0.1% Triton X-100, blocked and incubated overnight with 0.3% Triton X-100/10% fetal bovine serum in 1 $\times$ PBS containing AcH2K12 (Abcam) and visualized with a fluorescently conjugated secondary antibody (Molecular Probes). Neuronal nuclei were stained with Hoechst 33342 (Invitrogen). Images were acquired using a confocal microscope (LSM 510, Zeiss) at identical settings at the highest intensity for each of the conditions. Using the Hoechst signal channel, 20–40 representative non-apoptotic cells were chosen per experimental condition, and the mean AcH2K12 signal intensity was measured. Images were quantified using ImageJ 1.42q by an experimenter blind to treatment groups.

Statistics. Statistical analyses were performed using GraphPad Prism 5. One-way ANOVAs followed by Tukey's posthoc analyses or one-tailed Student's *t* tests were used unless indicated otherwise. All data are represented as mean $\pm$ SEM. Statistical significance was set at *p* = 0.05.



Funding sources

This research was funded by the Stanley Medical Research Institute, the JPB Foundation (L.H.T.) and the NIH/NIDA (S.J.H., R01DA028301)

Conflict of interest disclosure

L.H.T., S.J.H. and E.B.H. are consultants to Rodin Therapeutics which has licensed compounds from the Broad Institute.

Acknowledgements

We would like to thank Dr Steve Johnston for analytical/purification support and Nhien Le for compound management support.

Notes and references

‡ 1 mg kg⁻¹ dose of BRD6688 was chosen due to tolerability issues observed at 10 mg kg⁻¹: mortality in 5 out of 10 mice over 10 day treatment due to unknown cause in a single study. No toxicity was observed CK-p25 mice treated at 1 mg kg⁻¹ or in wild-type male C57BL/6 mice treated at 30 mg kg⁻¹ daily for 10 consecutive days.

- 1 J. Gräff and L. H. Tsai, *Annu. Rev. Pharmacol. Toxicol.*, 2013, **53**, 311–330.
- 2 J. Gräff, D. Rei, J. S. Guan, W. Y. Wang, J. Seo, K. M. Hennig, T. J. Nieland, D. M. Fass, P. F. Kao, M. Kahn, S. C. Su, A. Samiei, N. Joseph, S. J. Haggarty, I. Delalle and L. H. Tsai, *Nature*, 2012, **483**, 222–226.
- 3 M. Weiwer, M. C. Lewis, F. F. Wagner and E. B. Holson, *Future Med. Chem.*, 2013, **5**, 1491–1508.
- 4 J. Gräff, N. F. Joseph, M. E. Horn, A. Samiei, J. Meng, J. Seo, D. Rei, A. W. Bero, T. X. Phan, F. Wagner, E. Holson, J. Xu, J. Sun, R. L. Neve, R. H. Mach, S. J. Haggarty and L. H. Tsai, *Cell*, 2014, **156**, 261–276.
- 5 T. Abel and R. S. Zukin, *Curr. Opin. Pharmacol.*, 2008, **8**, 57–64.
- 6 M. Mahgoub and L. M. Monteggia, *Neurotherapeutics*, 2013, **10**, 734–741.
- 7 D. M. Fass, M. M. Kemp, F. A. Schroeder, F. F. Wagner, Q. Wang and E. B. Holson, *Histone Acetylation and Deacetylation.*, Weinheim, 2012.
- 8 M. Haberland, R. L. Montgomery and E. N. Olson, *Nat. Rev. Genet.*, 2009, **10**, 32–42.
- 9 S. Minucci and P. G. Pelicci, *Nat. Rev. Cancer*, 2006, **6**, 38–51.
- 10 J. M. Alarcon, G. Malleret, K. Touzani, S. Vronskaya, S. Ishii, E. R. Kandel and A. Barco, *Neuron*, 2004, **42**, 947–959.
- 11 N. Govindarajan, P. Rao, S. Burkhardt, F. Sananbenesi, O. M. Schluter, F. Bradke, J. Lu and A. Fischer, *EMBO Mol. Med.*, 2013, **5**, 52–63.
- 12 J. S. Guan, S. J. Haggarty, E. Giacometti, J. H. Dannenberg, N. Joseph, J. Gao, T. J. Nieland, Y. Zhou, X. Wang, R. Mazitschek, J. E. Bradner, R. A. DePinho, R. Jaenisch and L. H. Tsai, *Nature*, 2009, **459**, 55–60.
- 13 G. Li, H. Jiang, M. Chang, H. Xie and L. Hu, *J. Neurol. Sci.*, 2011, **304**, 1–8.
- 14 M. Malvaez, S. C. McQuown, G. A. Rogge, M. Astarabadi, V. Jacques, S. Carreiro, J. R. Rusche and M. A. Wood, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 2647–2652.
- 15 S. C. McQuown and M. A. Wood, *Curr. Psychiatr. Rep.*, 2010, **12**, 145–153.
- 16 M. J. Morris, M. Mahgoub, E. S. Na, H. Pranav and L. M. Monteggia, *J. Neurosci.*, 2013, **33**, 6401–6411.
- 17 F. F. Wagner, M. Weiwer, M. C. Lewis and E. B. Holson, *Neurotherapeutics*, 2013, **10**, 589–604.
- 18 D. Kim, C. L. Frank, M. M. Dobbin, R. K. Tsunemoto, W. Tu, P. L. Peng, J. S. Guan, B. H. Lee, L. Y. Moy, P. Giusti, N. Broodie, R. Mazitschek, I. Delalle, S. J. Haggarty, R. L. Neve, Y. Lu and L. H. Tsai, *Neuron*, 2008, **60**, 803–817.
- 19 R. H. Wilting, E. Yanover, M. R. Heideman, H. Jacobs, J. Horner, J. van der Torre, R. A. DePinho and J. H. Dannenberg, *EMBO J.*, 2010, **29**, 2586–2597.
- 20 R. A. Copeland, D. L. Pompliano and T. D. Meek, *Nat. Rev. Drug Discovery*, 2006, **5**, 730–739.
- 21 J. C. Bressi, A. J. Jennings, R. Skene, Y. Wu, R. Melkus, R. De Jong, S. O'Connell, C. E. Grimshaw, M. Navre and A. R. Gangloff, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 3142–3145.
- 22 J. L. Methot, P. K. Chakravarty, M. Chenard, J. Close, J. C. Cruz, W. K. Dahlberg, J. Fleming, C. L. Hamblett, J. E. Hamill, P. Harrington, A. Harsch, R. Heidebrecht, B. Hughes, J. Jung, C. M. Kenific, A. M. Kral, P. T. Meinke, R. E. Middleton, N. Ozerova, D. L. Sloman, M. G. Stanton, A. A. Szewczak, S. Tyagarajan, D. J. Witter, J. P. Secrist and T. A. Miller, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 973–978.
- 23 O. M. Moradei, T. C. Mallais, S. Frechette, I. Paquin, P. E. Tessier, S. M. Leit, M. Fournel, C. Bonfils, M. C. Trachy-Bourget, J. Liu, T. P. Yan, A. H. Lu, J. Rahil, J. Wang, S. Lefebvre, Z. Li, A. F. Vaisburg and J. M. Besterman, *J. Med. Chem.*, 2007, **50**, 5543–5546.
- 24 C. J. Chou, D. Herman and J. M. Gottesfeld, *J. Biol. Chem.*, 2008, **283**, 35402–35409.
- 25 A. M. Kral, N. Ozerova, J. Close, J. Jung, M. Chenard, J. Fleming, B. B. Haines, P. Harrington, J. Maclean, T. A. Miller, P. Secrist, H. Wang and R. W. Heidebrecht Jr, *Biochemistry*, 2014, **53**, 725–734.
- 26 B. E. Lauffer, R. Mintzer, R. Fong, S. Mukund, C. Tam, I. Zilberleyb, B. Flicke, A. Ritscher, G. Fedorowicz, R. Vallerio, D. F. Ortwine, J. Gunzner, Z. Modrusan, L. Neumann, C. M. Koth, P. J. Lupardus, J. S. Kaminker, C. E. Heise and P. Steiner, *J. Biol. Chem.*, 2013, **288**, 26926–26943.
- 27 J. L. Methot, D. M. Hoffman, D. J. Witter, M. G. Stanton, P. Harrington, C. Hamblett, P. Siliphaivanh, K. Wilson, J. Hubbs, R. Heidebrecht, A. M. Kral, N. Ozerova, J. C. Fleming, H. Wang, A. A. Szewczak, R. E. Middleton, B. Hughes, J. C. Cruz, B. B. Haines, M. Chenard, C. M. Kenific, A. Harsch, J. P. Secrist and T. A. Miller, *ACS Med. Chem. Lett.*, 2014, **5**, 340–345.
- 28 Y. J. Seo, Y. Kang, L. Muench, A. Reid, S. Caesar, L. Jean, F. Wagner, E. Holson, S. J. Haggarty, P. Weiss, P. King, P. Carter, N. D. Volkow, J. S. Fowler, J. M. Hooker and S. W. Kim, *ACS Chem. Neurosci.*, 2014, **5**, 588–596.



- 29 L. Riva, S. M. Blaney, R. Dauser, J. G. Nuchtern, J. Durfee, L. McGuffey and S. L. Berg, *Clin. Cancer Res.*, 2000, **6**, 994–997.
- 30 Y.-L. Zhang, E. Holson and F. F. Wagner, WO 2013067391, 2013.
- 31 M. Rai, E. Soragni, C. J. Chou, G. Barnes, S. Jones, J. R. Rusche, J. M. Gottesfeld and M. Pandolfo, *PLoS One*, 2010, **5**, e8825.
- 32 F. F. Wagner, D. E. Olson, J. P. Gale, T. Kaya, M. Weiwer, N. Aidoud, M. Thomas, E. L. Davoine, B. C. Lemerrier, Y. L. Zhang and E. B. Holson, *J. Med. Chem.*, 2013, **56**, 1772–1776.
- 33 J. A. Burkhard, C. Guerot, H. Knust and E. M. Carreira, *Org. Lett.*, 2012, **14**, 66–69.
- 34 Y. Wang, Y. L. Zhang, K. Hennig, J. P. Gale, Y. Hong, A. Cha, M. Riley, F. Wagner, S. J. Haggarty, E. Holson and J. Hooker, *Epigenetics*, 2013, **8**, 756–764.
- 35 D. M. Fass, S. A. Reis, B. Ghosh, K. M. Hennig, N. F. Joseph, W. N. Zhao, T. J. Nieland, J. S. Guan, C. E. Kuhnle, W. Tang, D. D. Barker, R. Mazitschek, S. L. Schreiber, L. H. Tsai and S. J. Haggarty, *Neuropharmacology*, 2013, **64**, 81–96.
- 36 M. Naldi, N. Calonghi, L. Masotti, C. Parolin, S. Valente, A. Mai and V. Andrisano, *Proteomics*, 2009, **9**, 5437–5445.
- 37 R. S. Broide, J. M. Redwine, N. Aftahi, W. Young, F. E. Bloom and C. J. Winrow, *J. Mol. Neurosci.*, 2007, **31**, 47–58.
- 38 J. C. Cruz, H. C. Tseng, J. A. Goldman, H. Shih and L. H. Tsai, *Neuron*, 2003, **40**, 471–483.
- 39 A. Fischer, F. Sananbenesi, P. T. Pang, B. Lu and L. H. Tsai, *Neuron*, 2005, **48**, 825–838.
- 40 P. Giusti-Rodriguez, J. Gao, J. Gräff, D. Rei, T. Soda and L. H. Tsai, *J. Neurosci.*, 2011, **31**, 15751–15756.
- 41 O. Bruserud, C. Stapnes, E. Ersvaer, B. T. Gjertsen and A. Rynningen, *Curr. Pharm. Biotechnol.*, 2007, **8**, 388–400.

